Executive Summary Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access…
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam
Executive Summary Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially To date, cell therapies have been approved in the US by the Food and Drug Administration…
Three digital health technologies have been developed to treat opioid use disorder (OUD). These applications, reSET-O (Pear Therapeutics), Connections (Chess Health) and DynamiCare (DynamiCare Health) [...]
Written by Tom Rutkowski, Jay Galli, and Kate Watkins
Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare [...]
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake. Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization [...]
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited [...]